FDA panel to consider simplifying COVID-19 vaccine use
A Food and Drug Administration advisory committee is scheduled to vote Thursday on whether to simplify current COVID-19 vaccine use so that all primary series and booster doses administered in the U.S. would be bivalent. The committee also is expected to discuss simplifying future COVID-19 vaccine use to authorize or approve a two-dose series for certain young children, older adults and people with compromised immunity and only one dose for all other individuals; as well as periodic updates to COVID-19 vaccines, including for use this fall.
Related News Articles
Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…
Headline
In time for back-to-school health screenings, AHA Aug. 25 released an infographic on strategies that clinicians and the Centers for Disease Control and…
Headline
Receiving a COVID-19 mRNA vaccine or booster during pregnancy can benefit pregnant people and their newborn infants, according to findings from a federally…
Chairperson's File
It’s been about 65 years since an effective vaccine was first used worldwide against poliomyelitis, or polio. Until then, polio was responsible for about 500,…